Lisa Leypoldt

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Lisa Leypoldt, Diana Tichy, Britta Besemer et al. · Journal of Clinical Oncology · 2023 · 141 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial

K. Elias, Uta Bertsch, Ema Požek et al. · Journal of Clinical Oncology · 2024 · 62 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

Franziska Brauneck, Pauline Weimer, Julian Schulze zur Wiesch et al. · Frontiers in Medicine · 2021 · 39 citations · Full text

Life Sciences, Hematology, Immunology +17

Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies

Matthew J. Rees, Mattia D’Agostino, Lisa Leypoldt et al. · American Society of Clinical Oncology Educational Book · 2024 · 39 citations

Medicine, Hematology, Oncology +17

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment

Susanne Ghandili, Martin Schönlein, Marc Lütgehetmann et al. · Cancers · 2021 · 34 citations · Full text

Veterinary Medicine, Hematology, Immunology +17